Phase 2 N=52 Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
Gastric Adenocarcinoma · Barrett Esophagus
Primary: Objective Response Rate (ORR) — 3.92 Participants (%)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
Gastric Cancer
Primary: Overall Response Rate (ORR) in Subjects Treated With FLX475 in Combination With Pembrolizumab — 0; 60.0 percentage of participants
Phase 2 N=18 Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
N/A N=20 Endoscopic Suturing for Primary Obesity Treatment
Obesity · Body Weight · Overweight
Primary: Number of Participants With Adverse Events — 5; 2; 0; 13 Participants
N/A N=452 Study of Impact of Not Measuring Residual Gastric Volume on Nosocomial Pneumonia Rates
Ventilation-Associated Pneumonia
Primary: Compare Ventilator Associated Pneumonia Rates in Patients Receiving Early Enteral Feeding Without Residual Gastric Volume (RGV) Monitoring and in Patients With RGV…
Phase 2 N=37 Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome
Gastric Cancer · Gastric Neoplasms
Primary: Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1)…
N/A N=76 Proteiomic Fingerprints of Gastric Juice
Gastric Cancer
Primary: Number of Participants With Accurate Diagnosis for Gastric Cancer — 27; 44 participants
N/A N=126 Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia
Stomach Neoplasms · Metaplasia
Primary: Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy — 78.5; 94.4; 89.2; 67.1 percentage of lesions
Phase 2 N=14 Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma
Morbid Obesity
Primary: Primary Outcome: Change in Body Weight — 9.6 kg
Phase 2 N=27 Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers
Healthy Volunteer
Primary: Fasting Gastric Volume as Measured by Single Photon Emission Computed Tomography (SPECT) — 178.8; 191.1 mL
N/A N=55 Effects of Gastric Bypass Surgery and Calcium Metabolism and the Skeleton
Obesity, Morbid · Gastric Bypass
Primary: Change in Intestinal Calcium Absorption — -25.8 % of ingested calcium that is absorbed
Phase 4 N=121 Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding
Esophageal and Gastric Varices
Primary: Rebleeding From Gastric Varices — 14; 21 Participants
Phase 2 N=138 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Oesophageal Squamous Cell Carcinoma · Gastric Cancer · Hepatocellular Carcinoma
Primary: Cohort A: Objective Response Rate (ORR) — 20.0 percentage of participants
Phase 2 N=38 Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Esophageal Cancer · Stomach Cancer
Primary: 10-month Progression-Free Survival Rate — 40.0 probability (%)
Phase 2 N=254 Docetaxel and Oxaliplatin in Gastric Cancer
Stomach Neoplasms
Primary: Time to Progression — 4.50; 7.66; 5.55 Months